Lv53
1078 积分 2024-05-09 加入
1069eP Crossover-adjusted overall survival (OS) benefit with sintilimab in EGFR-TKI-resistant NSCLC: Post-hoc analysis of ORIENT-31
17小时前
待确认
中药开元冲剂对实验性大鼠子宫内膜异位症的药效研究
3个月前
已完结
Adjuvant Durvalumab in Completely Resected Early-Stage Non–Small Cell Lung Cancer
3个月前
已完结
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
3个月前
已完结
Cancer burden and control in China: landscape, trends and challenges
4个月前
已完结
Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2)
4个月前
已完结
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
5个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
5个月前
已完结
Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC
6个月前
已完结